PDCD1 and synovial sarcoma: The results showed that SS subtype III had a significantly elevated T cell dysfunction score when compared with subtypes I and II, also suggest a distinct immune evasion strategy within SS subtype III and imply that patients with this subtype might exhibit greater responsiveness to therapeutic agents aimed at PD‐1 or PD‐L1 inhibition.